Bioestimuladores e seus mecanismos de ação

Cunha, Marisa Gonzaga da; Engracia, Marcela; Souza, Luciana Gasques de; Filho, Carlos D'Apparecida Machado

doi:10.5935/scd1984-8773.20201221424

Cited by 12 publications

(49 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Between seven and 10 days after the implant introduction, the macrophages secrete chemotactic and growth factors to trigger the attraction of fibroblasts and the proliferative phase of reconstruction. Fibroblasts secrete components of the extracellular matrix, initially type I collagen followed by a smaller production of type III collagen 5,6 …”

Section: Discussionmentioning

confidence: 99%

“…Therefore, neocollagenesis and the consequent increase of dermal tissue, which establishes the desired cosmetic result, are obtained by marked fibroblastic activity and proliferation around each particle. It will be followed by the PLLA degradation in monomers of lactic acid through hydrolysis without any indication of acute inflammatory response 5,7,11 …”

Section: Discussionmentioning

confidence: 99%

“…Right after the administration of PLLA, the injected volume promotes changes that can clearly be noted. Such changes may remain for 2 or 3 days until the total absorption of the diluent, 5,6 which was clinically identical between both presentations (Figure 4a,b).…”

Section: Discussionmentioning

confidence: 99%

“…Such response is subject to the characteristics of the injected product, the technique used regarding the administration of the injections in the tissue and the characteristics of each patient. 5 Biocompatible and biodegradable, the PLLA is an injectable synthetic polymer of the alpha-hydroxy acids family of amphiphilic nature, which forms colloidal micelles in water. 5 The product is available in vials in the form of lyophilized powder with particles whose diameter range from 40 to 63 μm.…”

Section: Introductionmentioning

confidence: 99%

“…5 Biocompatible and biodegradable, the PLLA is an injectable synthetic polymer of the alpha-hydroxy acids family of amphiphilic nature, which forms colloidal micelles in water. 5 The product is available in vials in the form of lyophilized powder with particles whose diameter range from 40 to 63 μm. [5][6][7] The use of two brands will be compared here: Sculptra®, containing 150 mg of PLLA and 90 mg of croscarmellose sodium, a polymer with cross-linked carboxymethyl cellulose 8 (0.6 ratio), 6 and Rennova ELLEVA®, containing 210 mg of PLLA with a more uniform granulometric distribution of the microparticles and 132 mg of sodium carboxymethyl cellulose (0.63 ratio).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Static and dynamic high‐resolution ultrasound analysis of tissue distribution of poly‐L‐lactic acid particles during subdermal application in two different presentations

Cunha

Sigrist

2022

Skin Health and Disease

View full text Add to dashboard Cite

Background All the changes the skin goes through, peaking at flaccidity, occur in the dermis and hypodermis, leading to loss of support and a lower capacity to totally accommodate displacements or any loss of subjacent volume, bringing about the onset of furrows and sagging. Improvements in facial sagging may be obtained with the administrations of substances like poly‐L‐lactic acid (PLLA), which triggers a tissue response through a controlled inflammatory reaction. Objectives Compare the tissue distribution of the particles of PLLA of both products available in Brazil (Sculptra® and Rennova Elleva®) during and immediately after their subdermal administrations, with 22G cannulas, through high‐resolution ultrasound imaging. Methods A total of four patients aged between 18 and 64 years had the inner part of the upper arms divided into eight quadrants and treated with 16 ml of each product, reconstituted to correspond to 9.5 mg/ml. The sites where PLLA was injected were analyzed through the high‐resolution ultrasound during (dynamic imaging) and immediately after the procedures (static imaging). Results During Sculptra® injection, high‐resolution ultrasound revealed that its distribution did not follow the trajectory of the cannula homogeneously. It was characterized by a more hyperechogenic central portion and an anechogenic peripheral portion, forming discrete posterior acoustic shadowing at times. Regarding Rennova ELLEVA® injection, the high‐resolution ultrasound analysis showed a homogeneous distribution of the product across the subcutaneous tissue following the trajectory of the cannula without formation of significant interface with the surrounding tissue, maintaining the sonographic aspect of thinly granulated hyperechogenic deposits, with strong posterior acoustic shadowing during and immediately after its administration. Conclusion Static and dynamic high‐resolution ultrasound imaging show a more homogenous distribution of PLLA particles with the use of Rennova ELLEVA® when compared with Sculptra®, which may induce the formation of capsules and a subsequent more dispersed fibroplasia, with larger area of action and a possible better therapeutic result. The interest of this article lies in its originality, highlighting the differences in the tissue distribution of two different brands of PLLA particles, which can impact the clinical response to the two products ‐ which we are researching and seems to interfere with the increase in dermal thickness.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Static and dynamic high‐resolution ultrasound analysis of tissue distribution of poly‐L‐lactic acid particles during subdermal application in two different presentations

Cunha

Sigrist

2022

Skin Health and Disease

View full text Add to dashboard Cite

show abstract

Analysis of satisfaction patient and increased dermis thickness by medical evaluation and USG by Rennova Elleva in the treatment of sagging skin on the inner part of the arms

Cunha

Ferregutti

Bernardo

et al. 2022

Skin Health and Disease

View full text Add to dashboard Cite

Introduction The flaccidity of the skin is provoked by changes caused by the chronological ageing of the skin, such as epidermal, dermal, and hypodermic thinning, which, in turn, are aggravated by photo ageing and by several other factors such as, for example, limited diets low in proteins, rapid weight loss and low BMI, liposuction, post‐pregnancy and stretch marks, which facilitate the loss of skin elasticity, even in young patients. Its treatment remains a major therapeutic challenge, as there are few procedures designed to effectively improve it. Objective To evaluate the satisfaction patient and increased dermis of Rennova Elleva in the treatment of cutaneous flaccidity of the inner part of the arms. Methods Twenty six women aged between 31 and 60 years old complaining of skin flaccidity in the medial area of the arms, with a severity score between: 1 (11 patients), 2 (10 patients) and 3 (5 patients) according to the scale Investigator Assessment Skin Laxity Scoring System (IASLSS), were treated with two applications of poly‐L‐lactic acid (PLLA) with intervals of 45 days between them. Results Forty five days after the second application of PLLA (D90), all patients presented a moderate to high degree of satisfaction with the treatment, with good tolerability and no adverse effects. Improvement was confirmed by high‐resolution ultrasound with an increase in dermal thickness between 23% and 70% (average value: 46%). Discussion Rennova Elleva® PLLA promoted an improvement in skin flaccidity and an increase in dermal thickness with good to excellent tolerability by patients. Conclusion The new presentation of PLLA proved to be effective and safe for the treatment of skin flaccidity.

show abstract

A Retrospective Analysis of Safety in Participants Treated with a Hybrid Hyaluronic Acid and Calcium Hydroxyapatite Filler

Braz,

Colucci,

Macedo de Oliveira

et al. 2024

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Background: Limited long-term safety data are published on HA/CaHA/L, a hybrid dermal filler combining hyaluronic acid (HA), calcium hydroxyapatite (CaHA), and lidocaine (L). Methods: This retrospective multicenter study assessed treatment-emergent adverse events (TEAEs) in adults treated with HA/CaHA/L. The full analysis set (FAS) included eligible consented adults (N = 403); the long-term safety analysis (LTSA) set included FAS participants with greater than or equal to 12-months HA/CaHA/L exposure (n = 243). Results: Participants were majority female (94.0%), with Fitzpatrick skin phototypes II/III (80.1%) and a mean age of 50.1 years. Most participants (86.4%) received one HA/CaHA/L treatment. The median time between participants’ first HA/CaHA/L treatment and chart review was 15.4 months. Participants received a mean of 2.2 mL (0.5-8.9 mL) filler per treatment. Treated areas were predominantly malar (71.2%) and mandible (69.7%) regions. Most participants (95.0%) had one or more aesthetic treatments other than HA/CaHA/L [eg, other dermal fillers (84.1%), botulinum toxin (63.3%)]. Nineteen (4.7%) FAS participants had 20 documented TEAEs; most (3.5%, n = 14 participants) were mild in severity. Twelve TEAEs in 11 participants (2.7%) were related to HA/CaHA/L: induration (three, 0.7%), edema (3, 0.7%), and implant site nodules (five, 1.2%), which were noninflammatory and likely related to product placement. Among the LTSA, 15 (6.2%) participants had 16 documented TEAEs (six edema, five implant site nodules, one inflammation, three skin induration, one hypersensitivity); most were mild in severity. Nine TEAEs in eight participants (3.3%) were HA/CaHA/L-related. No treatment-emergent serious AEs were reported. Conclusion: The data from this noninterventional retrospective study support the favorable longer term (>12 month) safety profile of HA/CaHA/L.

show abstract

Bioestimuladores e seus mecanismos de ação

Cited by 12 publications

References 0 publications

Static and dynamic high‐resolution ultrasound analysis of tissue distribution of poly‐L‐lactic acid particles during subdermal application in two different presentations

Static and dynamic high‐resolution ultrasound analysis of tissue distribution of poly‐L‐lactic acid particles during subdermal application in two different presentations

Analysis of satisfaction patient and increased dermis thickness by medical evaluation and USG by Rennova Elleva in the treatment of sagging skin on the inner part of the arms

A Retrospective Analysis of Safety in Participants Treated with a Hybrid Hyaluronic Acid and Calcium Hydroxyapatite Filler

Contact Info

Product

Resources

About